I reported previously (Jun 2014) on the non-invasive urine test of Israel’s Nucleix for monitoring bladder cancer treatment. Following a multi-center, 400-patients clinical trial, Nucleix has received the CE Mark allowing it to market Bladder EpiCheck in the E.U.

https://www.israel21c.org/bladder-cancer-monitor-gets-ce-mark-lung-cancer-test-next/